Ranibizumab biosimilar (Formycon/Bioeq)

雷珠单抗生物类似药 (Formycon/Bioeq)

Report date: 2024/10/16 14:23:28

Base Information

Drug NameRanibizumab biosimilar (Formycon/Bioeq)
Drug Alias Name雷珠单抗生物仿制药 (Formycon/Bioeq)CIMERLIRanivisioFYB-201CHS-201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[8] 
Global Approved IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[8] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/08/02
Country/TerritoryCzechiaUnited StatesUkraine +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesFormycon AGBioeq Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesSandoz Group AGFormycon AGSanto Holding Gmbh +[7] 
Inactive CompaniesBioeq Gmbh
Active IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeS01LA04
Related LinksN/A